An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)
Top Cited Papers
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 114, 104662
- https://doi.org/10.1016/j.yrtph.2020.104662
Abstract
No abstract availableThis publication has 63 references indexed in Scilit:
- Use of functional imaging across clinical phases in CNS drug developmentTranslational Psychiatry, 2013
- Blood–brain barrier structure and function and the challenges for CNS drug deliveryJournal of Inherited Metabolic Disease, 2013
- An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity TestingToxicologic Pathology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent AssaysToxicologic Pathology, 2010
- A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer HazardsToxicologic Pathology, 2009
- The future of drug safety testing: expanding the view and narrowing the focusDrug Discovery Today, 2009
- Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discoveryBritish Journal of Pharmacology, 2008
- Prediction of 2-Year Carcinogenicity Study Results for Pharmaceutical Products: How Are We Doing?Toxicological Sciences, 2005
- A Performance Standard for Clinical and Functional Observational Battery Examinations of RatsJournal of the American College of Toxicology, 1996